BioDlink International Company Limited will table several key resolutions at its hybrid annual general meeting scheduled for 26 June 2026, 1:00 p.m. (HKT), combining a physical session in Wuxi and online participation.

Share Capital Proposals • Issue Mandate: Directors request authority to issue, transfer or sell treasury shares equal to up to 20% of the 772.79 million shares in issue as at the AGM date, representing a ceiling of 154.56 million shares. • Buy-back Mandate: Authority is also sought to repurchase up to 10% of issued shares, or 77.28 million shares. Repurchased shares may be cancelled or held in treasury in line with Hong Kong’s new treasury-share regime. • Extension Option: If both mandates are approved, the issuance limit may be enlarged by the number of shares actually repurchased.

Board Composition Five directors appointed on 29 April 2026 will stand for re-election: – Executive: Dr. Jincai Li (Chairperson) – Non-Executive: Mr. Xiaojie Xi – Independent Non-Executives: Mr. Xin Fan, Dr. Ulf Grawunder and Dr. Chaohong Hu

Auditor Rotation PricewaterhouseCoopers will retire at the AGM after serving since the 2019 listing. The Board, with Audit Committee endorsement, proposes appointing Deloitte Touche Tohmatsu as new auditor for the 2026 financial year. The estimated 2026 fee is RMB2.70 million, comprising RMB2.20 million for audit and RMB0.50 million for non-audit services. The change aims to enhance audit efficiency and align with controlling shareholder WuXi XDC, which also intends to engage Deloitte.

Shareholding Impact WuXi XDC currently owns 60.67% of BioDlink’s outstanding shares (468.85 million). Full exercise of the buy-back mandate would lift its stake to approximately 67.41%. The Board pledges to maintain the minimum 25% public float.

Key Timetable • Register closure: 23–26 June 2026 (both dates inclusive). • Proxy deadline: 1:00 p.m., 24 June 2026. • AGM: 26 June 2026.

All resolutions will be voted on by poll.